| 製品名 |
IL-1 |
IL-2 |
IL-3 |
IL-4 |
IL-5 |
IL-6 |
IL-8 |
IL-10 |
IL-12 |
IL-13 |
IL-15 |
IL-17 |
IL-23 |
IL-7 |
IL-33 |
IL-22 |
IL-18 |
純度 |
| ATP |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| Polyinosinic-polycytidylic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.40% |
| Disulfiram |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| Resatorvid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| Oxidopamine hydrobromide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.42% |
| iST2-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.58% |
| Raleukin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.40% |
| Dupilumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥99.2% |
| Necrosulfonamide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.61% |
| Deucravacitinib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Tocilizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.67% |
| Oxidopamine hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| Beta-Sitosterol (purity>98%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| Apilimod |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| Icotrokinra |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Bimekizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.52% |
| Fibrinogen (Bovine) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ritlecitinib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| Ustekinumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| Oxazolone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Lysophosphatidylcholines |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Omeprazole |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| Secukinumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥99.20% |
| Theophylline |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| Risankizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.37% |
| DC-Y13-27 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.52% |
| N-Acetyl-D-glucosamine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.5% |
| Gamma-glutamylcysteine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.53% |
| Lebrikizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Guselkumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.34% |
| JTE-607 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.27% |
| Benzbromarone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| Sodium metatungstate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Inclisiran sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.08% |
| LMT-28 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.75% |
| Ixekizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.00% |
| Hydrocortisone hemisuccinate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| Sodium chloride, for cell culture |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Astegolimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.00% |
| Inclisiran |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.48% |
| IRF1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.72% |
| ODN 2216 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.57% |
| Lusvertikimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.41% |
| Poly (I:C):Kanamycin (1:1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SC144 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.48% |
| Neochlorogenic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| Briakinumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
| Golimumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| ODN TTAGGG |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.87% |
| Nidanilimab (Nadunolimab) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Camoteskimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.56% |
| VJDT |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.68% |
| Anti-Mouse IL-4 Antibody (11B11) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| LY3509754 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.35% |
| Alendronic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥98.0% |
| Pyrrothiogatain |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.61% |
| Verekitug |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Daclizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
| Sonelokimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Inbakicept |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.06% |
| Diallyl Trisulfide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Elaidic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Anti-Mouse IL-23 p19 Antibody (G23-8) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.72% |
| Muscone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| IL-17A antagonist 1 |
|
|
|
|
|
|
|
|
|
|
|
IL-17A, IC50: 1.14 nM
IL-17A, Kd: 0.66 μM
|
|
|
|
|
|
99.74% |
| Apilimod mesylate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.58% |
| Bivalirudin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| IRBP(651-670) human, mouse |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.64% |
| Deltamethrin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| HS-276 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.93% |
| Ginsenoside Rh1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.72% |
| Tralokinumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.12% |
| Perfluorodecanoic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Muromonab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.74% |
| Guanosine 5'-diphosphate sodium, 96% (HPLC) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| Stapokibart |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.37% |
| Madecassic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Anti-Mouse IL-6 Antibody (MP5-20F3) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.36% |
| Vidofludimus |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.14% |
| AF12198 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Periplogenin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥99.70% |
| Lipoxin A4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.00% |
| Hyaluronic acid (Mw:1000-2000Da) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ivuxolimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
| Fezakinumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| BIRT 377 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| Ginsenoside Rc |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| APY0201 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.42% |
| Diacerein |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.42% |
| Forsythoside I |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Lactulose |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Peimine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Adrenocorticotropic hormone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.60% |
| Ordesekimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.08% |
| LC-04-045 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.56% |
| S7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.25% |
| IRF1-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| Thiabendazole |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Sodium thiosulfate (99%, water≤1.0%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| 7β-Hydroxycholesterol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.72% |
| Sodium thiocyanate, GR, 99% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.2% |
| Sinigrin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| Tryptanthrin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| STAT1/3-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| N-Acetyl-L-tryptophan |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| Sarilumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.36% |
| SB-273005 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Corynoline |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.84% |
| Ossirene |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| AX-024 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.73% |
| Protectin D1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.10% |
| Smurf1-IN-A01 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Y-320 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.03% |
| Mulberroside A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| CAN10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sinapaldehyde |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.71% |
| Rilonacept |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Temtokibart |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.23% |
| Anti-Mouse IL-1b Antibody (B122) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99% |
| Prednisone acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| Epinastine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Lauroyl-L-carnitine chloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| Chymostatin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Efineptakin alfa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.70% |
| NP3-253 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.78% |
| Adakitug |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
| Anti-Mouse IL-10 Antibody (JES5-2A5) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tomaralimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.42% |
| Anti-Mouse IL-2 Antibody (JES6-1A12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99% |
| CAY10594 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.64% |
| SC144 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.98% |
| Tributyrin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.91% |
| Calceolarioside B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| γ-Glutamylvaline |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| YM-90709 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| Aloin (mixture of A&B) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.36% |
| Benzoylpaeoniflorin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.35% |
| Ganoderma Lucidum/Reishi Extract |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 3-O-Methyldopa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.55% |
| Taurohyodeoxycholic acid sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.99% |
| Pep-1 (uncapped) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| Ac-YVAD-CHO |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.99% |
| NK7-902 diTFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| Ziltivekimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.75% |
| Epimedin A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.43% |
| Adrenocorticotropic hormone TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| Bivalirudin TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| Alisol A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.59% |
| Olokizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.54% |
| GSK-1070806 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.50% |
| AN-3485 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SB 203580 sulfone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.25% |
| Benralizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.1% |
| Kukoamine A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| IBI-363 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.60% |
| Etokimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Atinvicitinib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.62% |
| Cendakimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| IL-17 modulator 4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.19% |
| IRF5-CPP5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.23% |
| Gomisin N |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| ADP-β-S trilithium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Mouse IL-1R Antibody (JAMA-147) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Piperonylic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Phellodendrine chloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.68% |
| NP-1815-PX sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.51% |
| BRD6989 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.54% |
| GW-405833 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.91% |
| Parishin C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.24% |
| Broussonin E |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.11% |
| TMI-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.57% |
| Semapimod tetrahydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.18% |
| Gamma-glutamylcysteine TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Xelafaslatide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| Pectolinarin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| Artemisic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.62% |
| Militarine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| BMS-195614 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.5% |
| RCGD423 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| Prezalumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.23% |
| (20R)-Protopanaxadiol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| TriDAP dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.16% |
| Efmarodocokin alfa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
| Maresin 2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tilrekimig |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pinostrobin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.98% |
| Tetramethyluric acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.63% |
| Fusidic acid sodium salt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.64% |
| WWL229 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.49% |
| 5-Methoxy-DL-tryptophan |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.32% |
| Anti-Mouse Galectin-9 Antibody (RG9-1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| UF010 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| L6H21 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.19% |
| Tribuloside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.26% |
| NecroX-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.69% |
| Kaempferol 3-O-β-D-glucuronide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.47% |
| [10]-Shogaol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.78% |
| BAA473 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.93% |
| Reslizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.4% |
| Anti-Mouse/Human IL-7 Antibody (M25) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ML345 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.37% |
| Tabersonine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.13% |
| Gypenoside A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.79% |
| Geranial |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.51% |
| Vitexin-2"-O-rhamnoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.78% |
| Stem bromelain |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Praeruptorin E |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| BC-1471 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.69% |
| Vemircopan |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.61% |
| INF 195 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.58% |
| House Dust Mite Extract, from D.farinae |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ATP disodium salt, 100 mM Solution, PCR Grade |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cornuside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.99% |
| Hesperetin 7-O-glucoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.38% |
| TNP-ATP triethylammonium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.70% |
| Tubeimoside III |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| Oroxylin A-7-O-glucuronide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| IL4I1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| RO2959 monohydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GSK699 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.80% |
| Mycophenolate mofetil hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.17% |
| Theophylline (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.92% |
| Nadifloxacin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Edpetiline |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Negletein |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.55% |
| Malvidin-3-glucoside chloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.87% |
| Platycodin D2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.84% |
| Mergetpa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Armillarisin A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| D(+)-Raffinose pentahydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Vorbipiprant |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.89% |
| Nogapendekin alfa (his tag) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.62% |
| PQA-18 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.62% |
| Simepdekinra |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.05% |
| IL-15-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.79% |
| Clazakizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
| Chondroitin sulfate (from chicken) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.61% |
| Erepdekinra |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.63% |
| (2S)-OMPT triethylamine, in ethanol:chloroform (1:1), 98% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| Deacetylasperulosidic Acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.44% |
| MDL-811 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.68% |
| TREM-1 inhibitory peptide GF9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.41% |
| Astringin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.54% |
| Sodium chloride, for molecular biology |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| Arabinoxylan (Medium viscosity) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TL-895 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| Gynostemma Extract |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| Eupafolin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.60% |
| Casein hydrolysate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dihydrosanguinarine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.98% |
| (5Z,2E)-CU-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ocankitug |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
| 1-Tetradecanol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.34% |
| AX-024 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.23% |
| Vunakizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Melredableukin alfa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Saponarin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| BMP-4 (15-24) acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.30% |
| NO-prednisolone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
| LRH-1 agonist-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.58% |
| Graveoline |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Grosvenorine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.64% |
| PF-4878691 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| Suciraslimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cyanidin 3,5-diglucoside chloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.44% |
| Elubrixin tosylate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.14% |
| IL-17 modulator 3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.51% |
| Vopikitug |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.32% |
| Methylthiouracil |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Carminic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Rosarin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| Balsalazide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.65% |
| GW405833 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.59% |
| Meloside A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.72% |
| ASK1-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.13% |
| Veledimex |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.77% |
| GFH018 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.59% |
| Aristolochic acid D |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| GSK2618960 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Diethylcarbamazine citrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.01% |
| SP4206 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Remtolumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.24% |
| (+)-Medioresinol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.13% |
| VGX-1027 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.67% |
| House Dust Mite Extract, from D.pteronyssinus |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NEK7 degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Ginsenoside F3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.84% |
| Firsekibart |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tyk2-IN-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.58% |
| YQ128 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| NP3-562 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.16% |
| Theophylline monohydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Perfluoropentanoic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Suplatast (Tosilate) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.67% |
| Naphazoline hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.38% |
| Pentadecane |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.88% |
| (±)-Praeruptorin A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Terminolic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| Desoximetasone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.72% |
| Elsilimomab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.44% |
| Anti-IL-12 p70 Antibody (20C2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Epinastine hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| GlcNAc-MurNAc |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| EGR-1-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.13% |
| Navepdekinra |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.58% |
| QL-1200186 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| Fosfenopril |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.85% |
| Anti-Mouse IL-1a Antibody (ALF-161) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.99% |
| Isoprothiolane |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| 7,3',4'-Tri-O-methylluteolin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.28% |
| Ritlecitinib tosylate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.65% |
| Y11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.34% |
| Hydrangenol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.63% |
| β-Anhydroicaritin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.69% |
| Diethylcarbamazine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| HMGB1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.40% |
| γ-Hexalactone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| 13-Methylberberine chloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.16% |
| Flizasertib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Isoastragaloside I |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.49% |
| iNOs-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| RBN012811 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.79% |
| Balsalazide sodium hydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.61% |
| Lys-D-Pro-Thr |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.63% |
| GIBH-130 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.62% |
| Envudeucitinibum |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.56% |
| Bexatamig |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Noreugenin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.42% |
| Naphazoline nitrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.12% |
| IL-17A antagonist 3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.25% |
| Tibulizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.86% |
| Patiromer |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PROTAC IRAK4 degrader-13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.47% |
| Isoforskolin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Tucotuzumab celmoleukin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.797% |
| Sericin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ARN14494 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.08% |
| IL-17A modulator-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.44% |
| Di-O-methyldemethoxycurcumin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Darutoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| MK-1966 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Carebastine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.23% |
| TLR7/8 agonist 6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.93% |
| THR-123 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| SM-17 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| FIP22 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.53% |
| SMAP-29 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.18% |
| PF-07899895 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.83% |
| Madecassic acid (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| JAK1/2-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.36% |
| MOR-106 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GLPG4970 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.60% |
| Sugiol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| Undecane |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.66% |
| Anti-Mouse GITR Antibody (DTA-1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.47% |
| Alisol F |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| Linoleate sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| Brazikumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.408% |
| Gumokimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.95% |
| Lyn peptide inhibitor |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.35% |
| DOTA-Pep-1L TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.60% |
| Abdakibart |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.30% |
| BP79 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BML-280 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.64% |
| (R)-IL-17 modulator 4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.56% |
| TSLP-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.67% |
| ER-464195-01 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.72% |
| JTE-907 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.54% |
| Hecogenin acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.57% |
| GNE-6893 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| NLRP3 modulator 7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-17A modulator-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.80% |
| Vitexin-4''-O-glucoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| Wnt/β-catenin-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.34% |
| M199 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.55% |
| AM9053 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.36% |
| Imneskibart |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| PROTAC JAK1/2 degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.47% |
| Naphazoline |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| Pretilachlor |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.25% |
| Romilkimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tyrphostin A1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.96% |
| Donzakimig |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.67% |
| Conbercept |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.42% |
| (E)-Methyl 4-coumarate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.87% |
| Luteolin-4'-O-glucoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.36% |
| Anemoside A3-methyl 6-aminohexanoate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.62% |
| Coelonin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| APH02174 hemiformic |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Phellodendrine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.60% |
| TSLP modulator-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.61% |
| PY109 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.15% |
| Anti-Mouse IL-2 Antibody (S4B6-1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dectrekumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lauroyl-L-carnitine-d9 chloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| SI-W052 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Abrezekimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Y13g dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| Naamidine J |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.41% |
| PDE1-IN-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-CD19 Antibody (4G7) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98% |
| NLRP3-IN-79 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.10% |
| SU5201 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.45% |
| IL-2-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| PG-901 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.35% |
| Shizukaol B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 4'-Acetoxy resveratrol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Brazilein |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Tomentosin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.95% |
| Lauroyl-L-carnitine-d3 chloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| IL-17A inhibitor 2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| Lecankitug |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98% |
| Oleanolic acid 28-O-β-D-glucopyranoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.42% |
| PDE1-IN-9 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Hericene A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.08% |
| Netakimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-6 aptamer sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.85% |
| Momordicine I |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NDI-101150 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Veledimex (S enantiomer) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.17% |
| APH02174 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Elubrixin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Xeligekimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Perakizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.79% |
| Balekafusp alfa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 7,8-Dimethoxycoumarin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.75% |
| Lasrekibart |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ginsenoside Rg4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| IL13Rα2 D1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.17% |
| Pentadecane-d32 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.2% |
| Alcudacigib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lixarkitug |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99% |
| Ompekimig |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Mouse CD124/IL4RA Antibody (REGN1103) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TLR9 antagonist 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IX 207-887 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.96% |
| IL-17 modulator 1 disodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.38% |
| Zumilokibart |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Vitamin K2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥98.0% |
| PROTAC HPK1 Degrader-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Guanosine 5'-diphosphate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HJC0123 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.06% |
| Gimvekibart |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Calamenene |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Hidrosmin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Crusekitug |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (2S)-OMPT |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 35 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| nAChR antagonist 2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sinigrin hydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| IL4RPep-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CNTO-5825 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.18% |
| Isomucronulatol 7-O-glucoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.40% |
| RO2959 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.12% |
| IL4RPep-1 acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.61% |
| IL-6-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| Icotrokinra (hydrochloride) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| Tepilukimig |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sphingomab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CIDD-8633 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-1β-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.45% |
| Yangambin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.27% |
| cis-Mulberroside A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-17-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Revbekitug |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Icotrokinra acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.65% |
| Anflekitug |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Chitoheptaose |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥98.0% |
| CJM-112 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.65% |
| SMU-14a |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CU-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NFAT Transcription Factor Regulator-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.37% |
| BRD4-BD1/2-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.52% |
| 1,2,4-Trimethoxybenzene |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Rat IL-4 Antibody (OX-81) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gaultherin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.44% |
| PNRI-299 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NT-0527 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| Flt-3L-Ig (hum/hum) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98% |
| Eicosapentaenoyl serotonin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| SLP7111228 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.01% |
| Anti-CD160 Antibody (MAT 302) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 3-Acetyldeoxynivalenol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.38% |
| 6-Methoxymellein |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RP-54745 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.79% |
| Leucrose |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.53% |
| SIK2-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.06% |
| 3-Acetyldeoxynivalenol-13C17 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| Benzylurea |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| BMS-986251 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Veledimex racemate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥98.0% |
| IL-17 modulator 4 sulfate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ritlecitinib malonate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Theophylline sodium glycinate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 99 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AGN-190121 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| A-9758 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-72 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-42 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CX-659S |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| YSY01A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Balsalazide-d4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| IL-17-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maxadilan |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-83 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HPK1-IN-68 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GED 0507-34-Levo |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-54 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (14S,15R)-14-Deoxyoxacyclododecindione |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cm-CATH2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RORγt inverse agonist 35 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BLT1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| JS007 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CIAC101 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NEK7 degrader-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Benzo-17R-RvD2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-17-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lck Inhibitor III |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Epinastine hydrochloride (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Mouse IL-4 Antibody (BVD6-24G2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TRPM8 antagonist 4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| JWX-A0108 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DLX2323 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BMS-279700 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HSP90-IN-31 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ligusticum cycloprolactam |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HB-107 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Triptoquinone B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TLR9 antagonist 2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TLR4L 10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-IL-13 Antibody (C836) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Eps8 peptide 327 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1,4-Dihydroxy-2-naphthoic acid (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DGKα-IN-10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AHR agonist 10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 17 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 109 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (6R,7R)-Epoxy-1-oleanen-3-ol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-91 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AM9928 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AN-3485 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Y 25510 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Theophylline L-lysine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| THR-123 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CJ-14897 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Chamissonolide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MK169 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HS-276 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-17 modulator 6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| KB-0118 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RIPK1/RIPK3-PPI-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Y13g |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Neuroprotective agent 16 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HuMax-IL15 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| STING agonist-50 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ISP-VT |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IAV-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PROTAC HDAC6 degrader 7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cbl-b-IN-30 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| COX-2/5-LOX-IN-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pseudoginsenoside RT4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| KBD4466 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ZM734 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RIPK1-IN-38 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TQC2938 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PROTAC PDE4 degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Acutissimalignan B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Girolline |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SHP2-IN-45 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PD-1/PD-L1-IN-54 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| VO-OHPic |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Human/Mouse GRP78 Antibody (N88) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BuChE-IN-23 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MT204 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PARP14 inhibitor 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ppc-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Eftezirleukin alfa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NP3-742 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| sEH-IN-24 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AS2677131 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| JAK1-IN-20 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BChE/MAO-B-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HB-0017 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Multitarget AD-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-23 cyclic peptide inhibitor 281 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-24 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RAGE406R |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RO8323 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CKD-712 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HDAC3 degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BChE-IN-44 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Velvakiment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IDO1/TDO-IN-12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SIN 14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 111 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ephemeranthol A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ABT-147 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| LDDN-0003499 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 10(11)-Cl-BBQ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| JNK2/MKK7 PPI-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BMS-986010 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| rel-Talmapimod hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ANB004 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| STAT6-IN-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.53% |
| CHNQD-03005 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-IL6 Antibody (MH166) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PF-06817024 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tolododekin alfa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AN-2898 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Calonysterone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cathepsin L-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R-03201195 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-CD1a Antibody (OKT-6) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PHI-501 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Diacerein (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IIIM1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NPSR1 antagonist-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PF-04308515 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GSTO1-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IDO1-IN-34 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NOD1-RIPK2-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SLP7111228 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3/URAT1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TLR7/8 agonist 14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CN016 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SHIP1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SAR444200 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AS2795440 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| QX008N |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ganoderic acid K |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Hck-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cot-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| G721-0377 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HVF18-a3-d |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lipoxin A4-d5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| UM-203 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BPN-37440 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1α-Hydroxyvitamin D5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Etazolate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| d-T101 peptide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DT-5461 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HPK1-IN-64 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IRBP(651-670) human, mouse TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dendronobiloside D |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SGNLTKYWKKIWKPGIKKWIK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| STAT3-IN-46 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TNF-α-IN-19 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Keap1/Nrf2/ARE activator 2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SMU-3k |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Siaresinolic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TNF-α-IN-10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-17-IN-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Mouse IL-3 Antibody (MP2-8F8) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aritinercept |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| EP4 receptor antagonist 8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sodium chloride, United States Pharmacopeia (USP) Reference Standard |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Antiflammin-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| COX-2/HDAC6-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| COX-2/CaV2.2-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IC 100 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GV-001 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tilnoprofenic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| YM-I-26 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-85 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Serrumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Glucocorticoid receptor/IL-6-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CK-119 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-23 cyclic peptide inhibitor 105 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lemairamin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1-Prenyl-2-methoxy-6-formyl-8-hydroxy-9H-carbazole |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DOTA-Pep-1L |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| OSE-703 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TCR-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| F8-IL-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| N,N-Diethylacetamide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.68% |
| TriDAP |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Semapimod |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AHL-7160 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-6-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cannabitwinol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RTX-003 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lithocholic amide-C2-N(didecane) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gerilimzumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Glucocorticoid receptor/IL-6-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-86 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 95 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Norkurarinol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Glutathione trisulfide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RIPK2-IN-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SHR-1703 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| VAK-694 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NOD2 agonist 4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GSK702 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MNP2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AChE-IN-85 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Antiallergic agent-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| COX-2-IN-66 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| rel-(1S,2R)-Dihydro bupropion |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Altrakincept |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RS-0481 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BChE-IN-49 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Santamarine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.85% |
| Anti-inflammatory agent 115 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IKZF2-degrader 5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PNA5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Hs02 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Panaxytriol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MEDI-7836 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| STAT6-IN-12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HPN601 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-17 modulator 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ginsenoside Rh1 (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-6/RIPK3-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Myelopeptide-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-84 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| eeAChE-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AGN 225660 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NEK7 degrader-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| VEGFR-2-IN-40 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BMP-4 (15-24) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Multi-target kinase-IN-10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| QX-004N |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| LM-021 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.27% |
| TLR7 antagonist-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2-Hydroxy Imiquimod |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CD28-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SCH708980 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| sEH-IN-23 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-81 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IDO1-IN-27 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-87 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-77 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| F 991 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CNTO-6785 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| KHK2840 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| REGN-10597 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Vitedoamine A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Z169667518 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 5-Androstenetriol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Apoptosis inducer 42 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Isostrictiniin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| [10]-Shogaol (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CSF1R-IN-27 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (E/Z)-3-Hydroxylicochalcone A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 23ME-00610 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| COM503 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NTZ-24 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MR2938 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TCR-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| FM-303 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ilekudinol B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-88 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RORγ-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HPK1-IN-69 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| KSI-028 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MAO-A-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AD-35 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| β-Bisabolol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NFAT-133 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Chuanbeinone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| LPZ-51 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-1β-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PDE4-IN-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PTPRO-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| M802 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DC-PGKI |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| JNJ627 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-17-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DRAK1/2-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 112 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AVP-13358 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RORγt inverse agonist 37 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Asperflavin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IBI-325 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 5-LOX-IN-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Theophylline sodium acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TRC4186 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HS-276 formic |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GI-Y2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HPK1-IN-65 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NIK-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Malvidin-3-glucoside chloride (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Butrin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 15-LOX-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PDE3/4-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| c-(2'FdAMP-2'FdIMP) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TNF-α/IL-1β/IL-6-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CAY10512 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Immuno modulator-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CSL-360 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| JAK2/STAT3-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| K-832 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| C6 D-Threo Ceramide (d18:1/6:0) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Antioxidant agent-22 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| P53/TLR2 modulator-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lyn peptide inhibitor TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PROTAC IRAK4 degrader-14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TLR7 agonist 8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ENDO12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| KOR agonist 7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| FSVVPSPK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-17A-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SCH-900117 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Hydrostatin-TL1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Eupalestin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CDK6/9-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Kaempferol 3-O-(2G-glucosylrutinoside)-7-O-glucoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Nivocasan |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-89 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| N-Palmitoyl-D-glucosamine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Olcorolimus |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-YVAD-CHO acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cyanidin 3,5-diglucoside chloride (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| KZR-8445 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| sEH/AChE-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SHP1-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 107 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| KZR-8445 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MBL-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Akt/NF-κB/MAPK-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| cyclo-Cannabigerol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CLP-d2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| LY2189102 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Keap1-Nrf2-IN-25 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-75 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| VRT-18858 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HZD37-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ANB032 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CT-133 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| INCB191358 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TLR7/8 antagonist 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Arucadiol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DPP-4-IN-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| sEH-IN-21 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MK175 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| OSE-279 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DB-310 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GABAAR/5-HT2AR modulator-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ZL-1211 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DCLK1-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Geranylgeranyl pyrophosphate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Antibiofilm agent-21 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Epinastine-13C,d3 hydrobromide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/AKT-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Papiliocin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 7-O-Methyl glabranin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HDAC6-IN-80 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Glycolipid C34 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IL-6-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| KRN7000 analog 3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NF-κB-IN-20 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CF-Vanillin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RIPK1-IN-32 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CNTO4088 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BMS-986331 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Heparin disaccharide II-S trisodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Betamethasone succinate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| E5090 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Balsalazide disodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cyclo(L-Ile-D-Leu) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Xanthine oxidase-IN-21 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 4-Methoxycinnamic acid ethyl ester |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.72% |
| Pentadecane (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Hecubine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Decarine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aloin (mixture of A&B) (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dersalazine sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Hibiscetin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Glycoursodeoxycholic acid 3-sulfate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tabersonine hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.55% |
| CK-102 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GPR68 antagonist 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RPR-106541 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Heparin disaccharide III-S trisodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cer (t18:0/26:0) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Patrinoside aglucone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Bengamide B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BSF2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Periplogenin (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HPK1-IN-43 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (E)-Methyl 4-coumarate (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Madindoline A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Heparin disaccharide I-H trisodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Octyl decyldimethyl ammonium chloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Nadifloxacin (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Nadifloxacin-d5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-CD25/IL-2Rα Antibody (7G7B6) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R-348 choline |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Chitohexaose hexahydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cytokine-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Saponarin (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Berkeleyacetal C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cavidine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Vitexin-2"-O-rhamnoside (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Alisol A (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|